Transoft Solutions Acquires Advanced Mobility Analytics Group (AMAG)
Expands Transportation Safety and Operations Portfolio
VANCOUVER, BC / ACCESSWIRE / October 15, 2024 / Transoft Solutions Inc. ("Transoft") - a global leader in transportation engineering, analysis, and operations software - announced today that it has acquired Advanced Mobility Analytics Group Pty Ltd ("AMAG"), a leading developer of video-based analytics software to facilitate improved traffic safety and management of road infrastructure, headquartered in Brisbane, Australia.
The secure cloud-based SMART platform developed by AMAG supports Vision Zero and Safe Systems approaches globally. Using computer vision, big data analytics, and advanced econometrics, its predictive analytics help organizations to create a safer and better managed road infrastructure.
"We are delighted to welcome AMAG's employees to Transoft," said Daniel Shihundu, P.Eng., CEO at Transoft. "We feel there is an excellent cultural fit, and combining our talented teams will accelerate research and development. The technologies present in our companies, independently, are truly remarkable, and merging the SMART and TrafxSAFE products under one umbrella will create a platform with unique capabilities. It will also allow us to explore synergies with our other products and create a software ecosystem where safety analytics can contribute to multiple stages in infrastructure development, from planning and design through to operations and maintenance. The Brisbane office, in addition to our current location in Sydney, will strengthen our presence in Australia and Asia-Pacific."
"We are extremely excited to be joining Transoft," said Simon Washington, PhD, CEO of AMAG. "We enjoy cultural alignment, share the same vision, and with our combined technical expertise and software solutions, will be well positioned to serve the growing number of road safety and traffic operations projects in markets Transoft serves globally. Our latest continuous monitoring and decision support platform for traffic operations management has been gaining traction in several markets globally and is providing our customers with valuable infrastructure insights not possible with traditional sensor technologies. Through the Transoft offices and partner network, we are excited to offer this technology to additional markets across the globe."
The integration of AMAG's business activities into the Transoft organization will ensure that its customers experience a seamless transition and a continued high quality of customer care and service. AMAG and their SMART platform are welcome additions to Transoft's portfolio and mark another step forward in the company's commitment to road safety initiatives like Vision Zero. Simon Washington will lead the combined AMAG and Transoft safety teams under a single Safety and Traffic Operations business unit at Transoft.
About Transoft Solutions
Transoft Solutions develops innovative and highly specialized software for aviation, civil infrastructure, and transportation professionals. Since 1991, Transoft has remained focused on safety-oriented solutions that enable transportation professionals to work effectively and confidently. Our portfolio of planning, simulation, modeling, and design solutions are used in over 150 countries serving more than 50,000 customers across local and federal agencies, consulting firms, airport authorities, and ports. We take pride in providing the highest quality of customer support from our headquarters in Canada, and through our offices in Sweden, the United Kingdom, the Netherlands, Australia, Germany, India, Belgium, France, Spain, and China. For more information on Transoft's range of aviation, civil design, and traffic safety solutions, visit transoftsolutions.com
Contact Information
Media Relations
publicrelations@transoftsolutions.com
+1 604 244 8387 ext 2245
Related Images
SOURCE: Transoft Solutions Inc.
View the original press release on newswire.com.
Transoft Solutions Inc.
Subscribe to releases from Accesswire
Subscribe to all the latest releases from Accesswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Accesswire
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press Release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press Release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press Release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press Release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press Release
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom